CBOE vs CME: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CBOE and CME share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CBOE and CME exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Cboe Global Markets operates a family of exchanges spanning options, North American equities, European and Asia-Pacific markets, futures, and global FX, and it earns money primarily from transaction fees, market data, and access services. Its crown jewel is the proprietary volatility franchise: the VIX index, VIX futures and options, and SPX index options are exclusively listed on Cboe venues, giving it a durable niche that rivals cannot easily replicate. The Data Vantage segment (market data and analytics) adds a recurring, subscription-like revenue stream on top of the more volume-sensitive transaction business.

Full CBOE guide

CME Group operates the largest futures and options marketplace in the world, spanning six asset classes: interest rates, equity indexes, energy, agricultural commodities, metals and foreign exchange. It earns money mainly from clearing and transaction fees charged on every contract traded and cleared, plus market-data and information-services revenue, and it benefits from owning both the exchange and the clearinghouse that guarantees trades. Volumes rise with hedging demand and market volatility, which is why record average daily volume has been the main engine of recent results.

Full CME guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CBOE drivers: Proprietary volatility and index-options franchise; Recurring Data Vantage revenue.
• CME drivers: Record trading volumes; Interest-rate and volatility franchise.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Cboe's transaction revenue is tied to trading volumes and market volatility, so a prolonged calm, low-volume market environment can pressure its most profitable options and VIX products. For CME, revenue is cyclical and tied to trading volumes, so a prolonged low-volatility environment can depress activity and fees.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CBOE if you believe its drivers more; CME if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CBOE and CME guides.

CBOE. Cboe reported record Q1 2026 net revenue of roughly $729 million and adjusted EPS near $3.70, both well above analyst expectations, on strength in options and volatility products. Full-year 2025 delivered about 17 percent net revenue growth and strong EPS gains. The stock trades at a premium P/E in the high-20s, consistent with its moat and steady cash generation but leaving little margin for a volume slowdown.

CME. CME posted record FY2025 revenue of about $6.5 billion and net income near $4.1 billion, then opened 2026 with record Q1 revenue of roughly $1.88 billion, up 14 percent, and adjusted EPS of $3.36. The shares trade around $240 for a market cap near $87 billion, a trailing P/E of roughly 21, with a high blended dividend yield reflecting the regular-plus-variable payout structure.

Headline figures (approximate, JUNE 2026): CBOE shows net revenue (q1 2026) ~$729M (+29% YoY), total revenue (fy2025) ~$4.7B, adjusted diluted eps (q1 2026) ~$3.70 (+48% YoY), net income (q1 2026) ~$386M; CME shows revenue (ttm) ~$6.7B, fy2025 revenue ~$6.5B, net income (ttm) ~$4.2B, market cap ~$87B.

CBOE and CME are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CBOE and CME exposure against your real portfolio. It is not an investment adviser.